Table 2 Summary of outcomes of included studies

Rate of symptomatic hemorrhage

Baseline and after-treatment variables with symptomatic and asymptomatic

Following treatment with tenecteplase, there was a greater early clinical improvement with a median of 9 in comparison to alteplase’s median of 1 [13].

National Institutes of Health Stroke Scale score (NIHSS)

No significant difference between both scores because a majority of the score range fell between 0 and 4 for both interventions [16].

Functional outcome at 90 days

Modified Rankin Scale (mRS)

Both interventions shared the same effect [12, 16].

A higher proportion of patients showed a significant recovery using the tenecteplase intervention [15].

The proportion of patients with good functional outcome was 61% in the tenecteplase group and 57% in the alteplase group (odds ratio, 1.24; 95% CI 0.65–2.37).

Reperfusion rate after thrombectomy

Modified thrombolysis in cerebral infarction (mTICI)

Over the course of 90 days following the treatment, overall reperfusion rates were significantly higher than alteplase [13].

Tenecteplase was associated with significantly better reperfusion (P=0.004) and clinical outcomes than alteplase (P<0.0001) [15].